Evidence map›Paper›PMID 29107626›Full record

SynthesisNeuropharmacology2018

MRI measurements of Blood-Brain Barrier function in dementia: A review of recent studies.

Rajikha Raja, Gary A Rosenberg, Arvind Caprihan

2 registry-linked trialsAbstract readSystematic Review
In one paragraph

Synthesis in Neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05836766 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: A Phase Ⅱa,Prospective,Multicenter,Randomized, Double-blind,Placebo-controlled Parallel Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2023 to 2024Enrolled120ConditionsAcute Ischemic Stroke, Reperfusion, Large Vessel OcclusionArmsY-6 sublingual tablets, Placebo tablets of Y-6 sublingual tablet
NCT06138834 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Effects of Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke: A Phase Ⅱ, Randomized, Double-blind, Double-dummy, Placebo-controlled Parallel Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2023 to 2025Enrolled300ConditionsAcute Ischemic Stroke, Large Vessel Occlusion, ReperfusionArmsLow-dose Y-6 sublingual tablets, High-dose Y-6 sublingual tablets, Low-dose Cilostazol, High-dose Cilostazol, Placebo
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Simultaneous measurement of water transport across the blood-brain and blood-CSF barrier in the human brain with arterial spin labeling MRI.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. EStroke and vascular neurology · 2025
    Article
  11. Review
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Review
  18. Article
  19. Biomarkers of blood-brain barrier and neurovascular unit integrity in human cognitive impairment and dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Rajikha RajaMIND Research Network, Albuquerque, NM, USA. Electronic address: rraja@mrn.org.
Gary A RosenbergDepartment of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Arvind CaprihanMIND Research Network, Albuquerque, NM, USA.
Mind Research Network · USUniversity of New Mexico · US

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
University of New Mexico Clinical and Translational Science CenterUL1TR000041 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LARSON, RICHARD S · 2012 to 2014
$9.8M
Pathobiology of Vascular Cognitive ImpairmentR01NS052305 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ROSENBERG, GARY ALLEN · 2006 to 2016
$4.3M
NCATS NIH HHS UL1 TR001449NINDS NIH HHS R01 NS052305
6 · The paper itself

Abstract

Blood-brain barrier (BBB) separates the systemic circulation and the brain, regulating transport of most molecules to protect the brain microenvironment. Multiple structural and functional components preserve the integrity of the BBB. Several imaging modalities are available to study disruption of the BBB. However, the subtle changes in BBB leakage that occurs in vascular cognitive impairment and Alzheimer's disease have been less well studied. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) is the most widely adopted non-invasive imaging technique for evaluating BBB breakdown. It is used as a significant marker for a wide variety of diseases with large permeability leaks, such as brain tumors and multiple sclerosis, to more subtle disruption in chronic vascular disease and dementia. DCE-MRI analysis of BBB includes both model-free parameters and quantitative parameters using pharmacokinetic modelling. We review MRI studies of BBB breakdown in dementia. The challenges in measuring subtle BBB changes and the state of the art techniques are initially examined. Subsequently, a systematic review comparing methodologies from recent in-vivo MRI studies is presented. Various factors related to subtle BBB permeability measurement such as DCE-MRI acquisition parameters, arterial input assessment, T

Indexed as

Magnetic Resonance ImagingAnimalsBlood-Brain BarrierDementiaHumansBlood-brain barrier permeabilityDementiaDynamic contrast enhanced MRIVascular cognitive impairment

Identifiers

PMID29107626
PMCPMC6044415
OpenAlexW2767076030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.